Scibase AB Asset Resilience Ratio
Scibase AB asset resilience ratio. Scibase AB (SCIB) has an Asset Resilience Ratio of 43.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SCIB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Scibase AB (2012–2025)
Asset resilience ratio of Scibase AB from 2012 to 2025. This chart shows how Scibase AB's Asset Resilience Ratio has changed over time. Read SCIB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Scibase AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Scibase AB asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr22.60 Million | 43.33% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr22.60 Million | 43.33% |
Asset Resilience Insights
- Very High Liquidity: Scibase AB maintains exceptional liquid asset reserves at 43.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Scibase AB Industry Peers by Asset Resilience Ratio
Compare Scibase AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Scibase AB Asset Resilience Ratio by Year (2012–2025)
Scibase AB asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Scibase AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.33% | Skr22.60 Million ≈ $2.43 Million |
Skr52.17 Million ≈ $5.61 Million |
+25.11pp |
| 2024-12-31 | 18.22% | Skr11.24 Million ≈ $1.21 Million |
Skr61.73 Million ≈ $6.64 Million |
-34.82pp |
| 2023-12-31 | 53.04% | Skr34.12 Million ≈ $3.67 Million |
Skr64.33 Million ≈ $6.92 Million |
+15.26pp |
| 2022-12-31 | 37.77% | Skr18.83 Million ≈ $2.03 Million |
Skr49.85 Million ≈ $5.37 Million |
-39.00pp |
| 2021-12-31 | 76.77% | Skr65.61 Million ≈ $7.06 Million |
Skr85.46 Million ≈ $9.20 Million |
+6.86pp |
| 2020-12-31 | 69.92% | Skr41.43 Million ≈ $4.46 Million |
Skr59.25 Million ≈ $6.38 Million |
+12.61pp |
| 2019-12-31 | 57.31% | Skr26.46 Million ≈ $2.85 Million |
Skr46.16 Million ≈ $4.97 Million |
-25.92pp |
| 2018-12-31 | 83.23% | Skr67.51 Million ≈ $7.27 Million |
Skr81.11 Million ≈ $8.73 Million |
-2.77pp |
| 2017-12-31 | 86.01% | Skr110.02 Million ≈ $11.84 Million |
Skr127.91 Million ≈ $13.77 Million |
+2.81pp |
| 2016-12-31 | 83.20% | Skr84.95 Million ≈ $9.14 Million |
Skr102.11 Million ≈ $10.99 Million |
+78.75pp |
| 2012-12-31 | 4.45% | Skr1.06 Million ≈ $114.31K |
Skr23.87 Million ≈ $2.57 Million |
-- |
About Scibase AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more